Elicio Therapeutics Inc (ELTX) FinancialsELTXElicio Therapeutics Inc

Evaluating the bottom line, Elicio Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -774.56%, provide a clear picture of how effectively ELTX converts its operational activities into shareholder value.

In the context of the broader market, ELTX competes directly with industry leaders such as LONA and IMMP. With a market capitalization of $81.21M, it holds a leading position in the sector. When comparing efficiency, ELTX's gross margin of N/A stands against LONA's N/A and IMMP's 100.00%. Such benchmarking helps identify whether Elicio Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Elicio has reported consistent net income losses, with a net loss of $11.8 million in Q1 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The company has a current ratio of 2.77, which suggests it can cover its short-term liabilities, but its total equity has been negative recently.